Nicola Brownlow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nicola Brownlow has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Peter J. Parker
School of Cancer and Pharmaceutical Sciences, Comprehensive Cancer Centre, King’s College London, SE1 1UL, London, United Kingdom
4 shared publications - Nick J. Dibb
Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, London, UK
3 shared publications Tanya Pike
Protein Phosphorylation Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
3 shared publications- Manuel Mendoza
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France
2 shared publications A E Russell
Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, London, UK
1 shared publication- Adrian Thomas Saurin
Cancer Research, School of Medicine, University of Dundee
1 shared publication
Latest Publications
- Open Access
- 31 October 2025
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (12)
Roles of Srs2/PARI-family DNA helicases in NoCut checkpoint signaling and abscission regulation
The coordination of chromosome segregation with cytokinesis is crucial for maintaining genomic stability. Chromatin bridges, arising from DNA replication stress or catenated chromosomes, can interfere with this process, leading to genomic instability if not properly resolved. Here, we uncover that the budding yeast DNA helicase Srs2 is essential for delaying abscission in the presence of chromatin bridges, thereby preventing chromosome breakage during cytokinesis. We also find that its human paralog PARI delays abscission-associated events, including midbody severing and actin-patch disassembly, in human cells with chromatin bridges. Although PARI depletion does not lead to increased bridge breakage or binucleation, our data indicate that PARI has nonessential functions within the Aurora B–mediated abscission checkpoint pathway. These findings establish a key role of Srs2 in NoCut checkpoint signaling in yeast, and suggest a functionally related role of PARI in coordinating abscission timing with chromatin bridge resolution in human cells.
- 31 October 2025
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (12)
Open AccessRoles of Srs2/PARI-family DNA helicases in NoCut checkpoint signaling and abscission regulation
The coordination of chromosome segregation with cytokinesis is crucial for maintaining genomic stability. Chromatin bridges, arising from DNA replication stress or catenated chromosomes, can interfere with this process, leading to genomic instability if not properly resolved. Here, we uncover that the budding yeast DNA helicase Srs2 is essential for delaying abscission in the presence of chromatin bridges, thereby preventing chromosome breakage during cytokinesis. We also find that its human paralog PARI delays abscission-associated events, including midbody severing and actin-patch disassembly, in human cells with chromatin bridges. Although PARI depletion does not lead to increased bridge breakage or binucleation, our data indicate that PARI has nonessential functions within the Aurora B–mediated abscission checkpoint pathway. These findings establish a key role of Srs2 in NoCut checkpoint signaling in yeast, and suggest a functionally related role of PARI in coordinating abscission timing with chromatin bridge resolution in human cells.
- 18 May 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (10) , 1663-1673
STAT4 expression and activation is increased during mitosis in vitro and in vivo in skin‐ and mucosa‐derived cell types: implications in neoplastic and inflammatory skin diseases
Background: The signal transducer and activator of transcription‐4 (STAT4/Stat4) is a transcription factor known to convey signals from interleukin‐12, interleukin‐23, and interferon‐alpha/beta to the nucleus, resulting in activation of dendritic cells, T‐helper cell differentiation and production of interferon‐gamma.Objective: To demonstrate a novel role for STAT4 in cell mitosis.Results: Phosphoserine STAT4 (pSerSTAT4) is increased in cells undergoing mitosis and is distributed throughout the cytoplasm during this stage of the cell cycle, whilst phosphotyrosine STAT4 (pTyrSTAT4) is confined to the chromosomal compartment. This distinct pattern of pSerSTAT4 during mitosis is seen in vitro in human keratinocytes and in other cell types. This is also present in vivo in cells undergoing mitosis in normal skin, psoriasis and squamous cell carcinoma.Inhibition of STAT4 phosphorylation by lisofylline and depletion of STAT4 by RNA interference results in a delay in progression of mitosis and leads to a reduction in cells completing cytokinesis.Conclusion: Our data demonstrate that STAT4 plays a role in enabling the normal and timely division of cells undergoing mitosis.
- 18 May 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (10) , 1663-1673
STAT4 expression and activation is increased during mitosis in vitro and in vivo in skin‐ and mucosa‐derived cell types: implications in neoplastic and inflammatory skin diseases
Background: The signal transducer and activator of transcription‐4 (STAT4/Stat4) is a transcription factor known to convey signals from interleukin‐12, interleukin‐23, and interferon‐alpha/beta to the nucleus, resulting in activation of dendritic cells, T‐helper cell differentiation and production of interferon‐gamma.Objective: To demonstrate a novel role for STAT4 in cell mitosis.Results: Phosphoserine STAT4 (pSerSTAT4) is increased in cells undergoing mitosis and is distributed throughout the cytoplasm during this stage of the cell cycle, whilst phosphotyrosine STAT4 (pTyrSTAT4) is confined to the chromosomal compartment. This distinct pattern of pSerSTAT4 during mitosis is seen in vitro in human keratinocytes and in other cell types. This is also present in vivo in cells undergoing mitosis in normal skin, psoriasis and squamous cell carcinoma.Inhibition of STAT4 phosphorylation by lisofylline and depletion of STAT4 by RNA interference results in a delay in progression of mitosis and leads to a reduction in cells completing cytokinesis.Conclusion: Our data demonstrate that STAT4 plays a role in enabling the normal and timely division of cells undergoing mitosis.
- 19 January 2017
- Published by Taylor & Francis in Cell Cycle
- Vol. 16 (3) , 233-234
DNA replication stress: NoCut to the rescue
- 19 January 2017
- Published by Taylor & Francis in Cell Cycle
- Vol. 16 (3) , 233-234
DNA replication stress: NoCut to the rescue
- Open Access
- 22 December 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 13853
PKCɛ switches Aurora B specificity to exit the abscission checkpoint
The ‘NoCut’, or Aurora B abscission checkpoint can be activated if DNA is retained in the cleavage furrow after completion of anaphase. Checkpoint failure leads to incomplete abscission and a binucleate outcome. These phenotypes are also observed after loss of PKCɛ in transformed cell models. Here we show that PKCɛ directly modulates the Aurora B-dependent abscission checkpoint by phosphorylating Aurora B at S227. This phosphorylation invokes a switch in Aurora B specificity, with increased phosphorylation of a subset of target substrates, including the CPC subunit Borealin. This switch is essential for abscission checkpoint exit. Preventing the phosphorylation of Borealin leads to abscission failure, as does expression of a non-phosphorylatable Aurora B S227A mutant. Further, depletion of the ESCRT-III component and Aurora B substrate CHMP4C enables abscission, bypassing the PKCɛ–Aurora B exit pathway. Thus, we demonstrate that PKCɛ signals through Aurora B to exit the abscission checkpoint and complete cell division.
- 22 December 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 13853
Open AccessPKCɛ switches Aurora B specificity to exit the abscission checkpoint
The ‘NoCut’, or Aurora B abscission checkpoint can be activated if DNA is retained in the cleavage furrow after completion of anaphase. Checkpoint failure leads to incomplete abscission and a binucleate outcome. These phenotypes are also observed after loss of PKCɛ in transformed cell models. Here we show that PKCɛ directly modulates the Aurora B-dependent abscission checkpoint by phosphorylating Aurora B at S227. This phosphorylation invokes a switch in Aurora B specificity, with increased phosphorylation of a subset of target substrates, including the CPC subunit Borealin. This switch is essential for abscission checkpoint exit. Preventing the phosphorylation of Borealin leads to abscission failure, as does expression of a non-phosphorylatable Aurora B S227A mutant. Further, depletion of the ESCRT-III component and Aurora B substrate CHMP4C enables abscission, bypassing the PKCɛ–Aurora B exit pathway. Thus, we demonstrate that PKCɛ signals through Aurora B to exit the abscission checkpoint and complete cell division.
- Open Access
- 8 December 2014
- Published by Springer Nature in Nature Communications
- Vol. 5 (1) , 5685
Mitotic catenation is monitored and resolved by a PKCε-regulated pathway
Exit from mitosis is controlled by silencing of the spindle assembly checkpoint (SAC). It is important that preceding exit, all sister chromatid pairs are correctly bioriented, and that residual catenation is resolved, permitting complete sister chromatid separation in the ensuing anaphase. Here we determine that the metaphase response to catenation in mammalian cells operates through PKCε. The PKCε-controlled pathway regulates exit from the SAC only when mitotic cells are challenged by retained catenation and this delayed exit is characterized by BubR1-high and Mad2-low kinetochores. In addition, we show that this pathway is necessary to facilitate resolution of retained catenanes in mitosis. When delayed by catenation in mitosis, inhibition of PKCε results in premature entry into anaphase with PICH-positive strands and chromosome bridging. These findings demonstrate the importance of PKCε-mediated regulation in protection from loss of chromosome integrity in cells failing to resolve catenation in G2.
- 8 December 2014
- Published by Springer Nature in Nature Communications
- Vol. 5 (1) , 5685
Open AccessMitotic catenation is monitored and resolved by a PKCε-regulated pathway
Exit from mitosis is controlled by silencing of the spindle assembly checkpoint (SAC). It is important that preceding exit, all sister chromatid pairs are correctly bioriented, and that residual catenation is resolved, permitting complete sister chromatid separation in the ensuing anaphase. Here we determine that the metaphase response to catenation in mammalian cells operates through PKCε. The PKCε-controlled pathway regulates exit from the SAC only when mitotic cells are challenged by retained catenation and this delayed exit is characterized by BubR1-high and Mad2-low kinetochores. In addition, we show that this pathway is necessary to facilitate resolution of retained catenanes in mitosis. When delayed by catenation in mitosis, inhibition of PKCε results in premature entry into anaphase with PICH-positive strands and chromosome bridging. These findings demonstrate the importance of PKCε-mediated regulation in protection from loss of chromosome integrity in cells failing to resolve catenation in G2.
- 17 November 2014
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 42 (6) , 1534-1537
Regulation of the cytokinesis cleavage furrow by PKCε
- 17 November 2014
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 42 (6) , 1534-1537
Regulation of the cytokinesis cleavage furrow by PKCε
- 23 December 2009
- Published by Wiley in ChemMedChem
- Vol. 5 (1) , 130-139
Novel Imatinib Derivatives with Altered Specificity between Bcr–Abl and FMS, KIT, and PDGF Receptors
Imatinib is a clinically important ATP analogue inhibitor that targets the tyrosine kinase domain of the intracellular Abl kinase and the PDGF receptor family. Imatinib has revolutionised the treatment of chronic myeloid leukaemia, which is caused by the oncogene Bcr–Abl and certain solid tumours that harbor oncogenic mutations of the PDGF receptor family. As a leading kinase inhibitor, imatinib also provides an excellent model system to investigate how changes in drug design impact biological activity, which is an important consideration for rational drug design. Herein we report a new series of imatinib derivatives that in general have greater activity against the family of PDGF receptors and poorer activity against Abl, as a result of modifications of the phenyl andN‐methylpiperazine rings. These new compounds provide a platform for further drug development against the therapeutically important PDGF receptor family and they also provide insight into the engineering of drugs with altered biological activity.
- 23 December 2009
- Published by Wiley in ChemMedChem
- Vol. 5 (1) , 130-139
Novel Imatinib Derivatives with Altered Specificity between Bcr–Abl and FMS, KIT, and PDGF Receptors
Imatinib is a clinically important ATP analogue inhibitor that targets the tyrosine kinase domain of the intracellular Abl kinase and the PDGF receptor family. Imatinib has revolutionised the treatment of chronic myeloid leukaemia, which is caused by the oncogene Bcr–Abl and certain solid tumours that harbor oncogenic mutations of the PDGF receptor family. As a leading kinase inhibitor, imatinib also provides an excellent model system to investigate how changes in drug design impact biological activity, which is an important consideration for rational drug design. Herein we report a new series of imatinib derivatives that in general have greater activity against the family of PDGF receptors and poorer activity against Abl, as a result of modifications of the phenyl andN‐methylpiperazine rings. These new compounds provide a platform for further drug development against the therapeutically important PDGF receptor family and they also provide insight into the engineering of drugs with altered biological activity.
- 15 February 2009
- Published by Taylor & Francis in Cell Cycle
- Vol. 8 (4) , 549-555
Protein kinase C epsilon in cell division: Control of abscission
Cell division requires the separation and partitioning of sister chromatids to opposite ends of the cell before an actomyosin ring contracts the membrane in between during cytokinesis. The final irreversible step occurs during abscission when the ring breaks down and the membrane is sealed in its place. The physical mechanics of contraction depend on RhoA which is stimulated by a centralspindlin complex around the cell equator. However exactly how these events are reversed to allow actomyosin breakdown and abscission were not well understood. Here we will discuss new findings which implicate Protein Kinase C epsilon (PKCε) as a regulator of RhoA signalling required for abscission.
- 15 February 2009
- Published by Taylor & Francis in Cell Cycle
- Vol. 8 (4) , 549-555
Protein kinase C epsilon in cell division: Control of abscission
Cell division requires the separation and partitioning of sister chromatids to opposite ends of the cell before an actomyosin ring contracts the membrane in between during cytokinesis. The final irreversible step occurs during abscission when the ring breaks down and the membrane is sealed in its place. The physical mechanics of contraction depend on RhoA which is stimulated by a centralspindlin complex around the cell equator. However exactly how these events are reversed to allow actomyosin breakdown and abscission were not well understood. Here we will discuss new findings which implicate Protein Kinase C epsilon (PKCε) as a regulator of RhoA signalling required for abscission.
- 11 September 2008
- Published by Springer Nature in Leukemia
- Vol. 23 (3) , 590-594
Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor
- 11 September 2008
- Published by Springer Nature in Leukemia
- Vol. 23 (3) , 590-594
Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor
- 10 January 2008
- Published by Springer Nature in Leukemia
- Vol. 22 (7) , 1452-1453
Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro
- 10 January 2008
- Published by Springer Nature in Leukemia
- Vol. 22 (7) , 1452-1453
Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro